Kai-Xuan Li

Dr. Kai-Xuan Li

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2023 in Frontiers in Cell and Developmental Biology
Verified
Journal Article
Open access
LZLi Zhang
Li Zhang
YZYuhan Zhang
Yuhan Zhang
KLKai-Xuan Li
Kai-Xuan Li
SXShuai Xue
Shuai Xue
Tumor radioresistance remains a key clinical challenge. The Hedgehog (HH) signaling pathway and glioma-associated oncogene (GLI) are aberrantly activated in several cancers and are thought to contribute to cancer radioresistance by influencing DNA repair, reactive oxygen species production, apoptosis, autophagy, cancer stem cells, the cell cycle, and the tumor microenvironment. GLI is reported to activate the main DNA repair pathways, to interact with cell cycle regulators like Cyclin D and Cyclin E, to inhibit apoptosis via the activation of B-cell lymphoma-2, Forkhead Box M1, and the MYC proto-oncogene, to upregulate cell stemness related genes (Nanog, POU class 5 homeobox 1, SRY-box transcription factor 2, and the BMI1 proto-oncogene), and to promote cancer stem cell transformation. The inactivation of Patched, the receptor of HH, prevents caspase-mediated apoptosis. This causes some cancer cells to survive while others become cancer stem cells, resulting in cancer recurrence. Combination treatment using HH inhibitors (including GLI inhibitors) and conventional therapies may enhance treatment efficacy. However, the clinical use of HH signaling inhibitors is associated with toxic side effects and drug resistance. Nevertheless, selective HH agonists, which may relieve the adverse effects of inhibitors, have been developed in mouse models. Combination therapy with other pathway inhibitors or immunotherapy may effectively overcome resistance to HH inhibitors. A comprehensive cancer radiotherapy with HH or GLI inhibitor is more likely to enhance cancer treatment efficacy while further studies are still needed to overcome its adverse effects and drug resistance.

18 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
BYBin Ye
Bin Ye
KDKe Ding
Ke Ding
KLKai-Xuan Li
Kai-Xuan Li
QZquan zhu
quan zhu
Prostate cancer (PCa) is a common malignant disease among men and biochemical recurrence (BCR) is considered to be a decisive risk factor for clinical recurrence and PCa metastasis. Clarifying the genes related to BCR and its possible pathways is vital for providing diagnosis and treatment methods to delay the progress of BCR. An analysis of data concerning PCa from previous datasets of The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) was performed. Immunohistochemical (IHC) staining were used to evaluate the expression of SLC14A1 in prostate tissues. Kaplan–Meier analysis, Pearson correlation, and single sample Gene Set Enrichment Analysis (ssGSEA) were used to identify the potential pathway and molecular mechanism of the function of SLC14A1 in BCR of PCa. The expression of SLC14A1 is significantly reduced in prostate cancer cells and tissue comparing to normal prostate epithelial cell and para-cancerous tissue. As indicated by Kaplan–Meier analysis, High expression of SLC14A1 could increase the BCR-free survival time of PCa patients. This effect might be related to the interaction with miRNAs (has-miR-508, has-mir-514a2, and has-mir-449a) and the infiltration of B cells. SLC14A1 is a novel important gene associated with BCR of PCa, and further studies of its molecular mechanism may delay the progress of BCR.

16 May 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
XZXiaowei Zhou
Xiaowei Zhou
FLFanyan Luo
Fanyan Luo
BXBitao Xiang
Bitao Xiang
KLKai-Xuan Li
Kai-Xuan Li
Coronary artery disease (CAD) remains a leading global cause of mortality. The expression of small ubiquitin-like modifier 1 (SUMO-1) is reduced in heart failure. However, the mechanisms underlying its modification in CAD remain underexplored. This study sought to identify SUMOylation-related biomarkers and elucidate the potential mechanisms in CAD pathogenesis. This study analyzed three CAD datasets (GSE42148, GSE23561, and GSE121893) alongside 187 SUMOylation-related genes (SRGs). The overlap between differentially expressed genes (DEGs) and SRGs was used to identify differentially expressed SUMOylation-related genes (DE-SRGs). Biomarkers were validated through expression profiling and receiver operating characteristic (ROC) curve analysis. Enrichment and immune infiltration analyses were performed to explore the molecular mechanisms by which these biomarkers influence CAD. A drug-gene interaction network was constructed using the Drug-Gene Interaction database (DGIdb). Single-cell analysis was conducted to identify key cellular players and validate the differential expression of biomarkers across cell types. A total of 12 DE-SRGs were identified in CAD. Among them, SUMO1 and PPARG were validated as biomarkers, with their expression significantly elevated in the CAD group compared to the control group. Single-sample gene set enrichment analysis (ssGSEA) revealed distinct immune cell distributions in CAD, with central memory CD4+ T cells and memory B cells positively correlated with the biomarkers. Gene set enrichment analysis (GSEA) linked these biomarkers to ribosomal activity, olfactory transduction, and other pathways. Single-cell analysis confirmed the expression of SUMO1 and PPARG in endothelial cells, particularly in the CAD group. Additionally, SUMO1 was differentially expressed in cardiomyocytes, exhibiting higher expression in controls. SUMO1 and PPARG were identified as novel SUMOylation-related biomarkers in CAD, suggesting new therapeutic avenues for CAD management.

1 December 2021 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
MYMeihong Yu
Meihong Yu
KLKai-Xuan Li
Kai-Xuan Li
SZShishuang Zhou
Shishuang Zhou
HWHanyu Wang
Hanyu Wang
MLMeixian Le
Meixian Le
YTYuyong Tan
Yuyong Tan
Purpose: Sharp-pointed FBs with both sides embedded in the duodenal wall are rare. Compared with smooth edged FBs, sharp objects are more likely to be associated with significant adverse events, when penetrating the wall of the digestive tract. The clinical features of patients who experienced sharp-pointed FBs embedded in both sides of the duodenum were retrospectively analyzed, as were the efficacy and safety of endoscopic removal of these FBs. Patients and Methods: This retrospective study included 21 adults with both sides of sharp-pointed FBs embedded into the duodenal wall who were admitted to the Second Xiangya Hospital in China between January 1, 1996, and May 31, 2021. Data associated with the endoscopic removal of these FBs were collected from the electronic medical record system (EMRS) of the hospital. Results: The incidence rate of duodenal total FBs and FBs embedded in both sides was 8.87% and 1.03%, respectively. The success rate of endoscopic treatment was 100.00% in 124 patients without embedded duodenal FBs and 97.14% in 35 patients with one side embedded duodenal FBs. Of the 21 patients with FBs embedded in both sides of the duodenal wall, endoscopic removal was successful in 85.71% of patients, whereas 14.29% required surgery. FBs removed from these patients included toothpicks in 12; needles in 3; jujube pits in 2; and a chopstick, dentures, fish bones, and chicken bones in one each. Most of these 21 FBs were located in the bulb and descending duodenum, followed by the third part of duodenum. Conclusion: Sharp-edged FBs with both sides embedded in the duodenal wall are rare. Endoscopic removal may be considered as a feasible, safe, and effective method of removing sharp-pointed FBs with both sides embedded in the duodenal wall. And if endoscopic removal is unsuccessful, surgical management can be a secondary option.

4 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ZLZhongyi Li
Zhongyi Li
ZZZhihuan Zheng
Zhihuan Zheng
XLXuesong Liu
Xuesong Liu
QZquan zhu
quan zhu
KLKai-Xuan Li
Kai-Xuan Li
Zheng-Yan TangZheng-Yan Tang
Zheng-Yan Tang
Background: Venous thromboembolism (VTE) and postoperative hemorrhage are unavoidable complications of transurethral resection of the prostate (TURP). At present, more and more patients with benign prostate hyperplasia (BPH) need long-term antithrombotic therapy before operation due to cardiovascular diseases or cerebrovascular diseases. The purpose of this study was to investigate the effect of preoperative antithrombotic therapy history on lower extremity VTE and bleeding after TURP. Methods: Patients who underwent TURP in the Department of Urology, Xiangya Hospital, Central South University, from January 2017 to December 2021 and took antithrombotic drugs before operation were retrospectively analyzed. The baseline data of patients were collected, including age, prostate volume, preoperative International Prostate Symptom Score (IPSS), complications, surgical history within one month, indications of preoperative antithrombotic drugs, drug types, medication duration, etc. Main outcome measures included venous thromboembolism after TURP, intraoperative and postoperative bleeding, and perioperative blood transfusion. Secondary outcome measures included operation duration and postoperative hospitalization days, the duration of stopping antithrombotic drugs before operation, the recovery time of antithrombotic drugs after operation, the condition of lower limbs within 3 months after operation, major adverse cardiac events (MACEs), and cerebrovascular complications and death. Results: A total of 31 patients after TURP with a long preoperative history of antithrombotic drugs were included in this study. Six patients (19.4%) developed superficial venous thrombosis (SVT) postoperatively. Four of these patients progressed to deep vein thrombosis (DVT) without pulmonary thromboembolism (PE). Only one patient underwent extra bladder irrigation due to blockage of their urinary catheter by a blood clot postoperatively. The symptoms of hematuria mostly disappeared within one month postoperatively and lasted for up to three months postoperatively. No blood transfusion, surgical intervention to stop bleeding, lower limb discomfort such as swelling, MACEs, cerebrovascular complications, or death occurred in all patients within three months after surgery. Conclusion: Short-term preoperative discontinuation may help patients with antithrombotic therapy to obtain a relatively safe opportunity for TURP surgery after professional evaluation of perioperative conditions. The risks of perioperative bleeding, VTE, and serious cardiovascular and cerebrovascular complications are relatively controllable. It is essential for urologists to pay more attention to the perioperative management of these patients. However, further high-quality research results are needed for more powerful verification.

16 February 2022 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
HLHaozhen Li
Haozhen Li
KLKai-Xuan Li
Kai-Xuan Li
QZQuan Zhu
Quan Zhu
Zheng-Yan TangZheng-Yan Tang
Zheng-Yan Tang
ZWZhao Wang
Zhao Wang